Pomegranate-Derived Gut Metabolite Shows Promise for Heart Function in Early Studies

Heart failure is a complex condition that presents in several forms. While many people associate heart failure with a weakened heart that cannot pump blood effectively, approximately half of all heart failure patients suffer from a different mechanical problem: their heart muscle becomes too stiff to relax and fill with blood properly. This condition, known as heart failure with preserved ejection fraction (HFpEF), has historically been a significant challenge to manage.

However, a fascinating area of nutritional and functional medicine is shedding light on how our diet—and our gut microbiome—might offer new pathways to support heart muscle health. According to a recent preclinical study published in the journal Science Advances, a natural compound derived from the digestion of certain fruits and nuts may help improve heart function at the cellular level.

The Power of Pomegranates and the Gut Microbiome

The compound at the center of this research is called urolithin A. Interestingly, urolithin A is not found directly in the food we eat. Instead, it is a postbiotic—a beneficial byproduct created when specific bacteria in our gut digest polyphenols called ellagitannins. These precursor compounds are abundant in healthy, whole foods such as pomegranates, walnuts, pecans, raspberries, and strawberries.

When you eat a handful of walnuts or consume pomegranate seeds, your gut bacteria go to work breaking down the ellagitannins. If you have the right microbiome composition, this digestive process yields urolithin A, which is then absorbed into the bloodstream where it can interact with various tissues, including the heart.

What the Preclinical Evidence Shows

Researchers from King's College London recently investigated how urolithin A impacts the stiffness of the heart muscle. As reported in a press release from King's College London and detailed by Medical News Today, the research team conducted a series of experiments using animal models and engineered human heart tissue.

It is vital to note that this is early, preliminary evidence. The study was conducted in a laboratory setting using preclinical models, and these results have not yet been replicated in larger human clinical trials. However, these early laboratory findings provide a promising foundation for the future of nutritional cardiology.

The researchers observed that introducing urolithin A to the preclinical models resulted in significant functional improvements. Specifically, the compound helped the heart muscle cells relax more effectively. In HFpEF, the heart's inability to relax means it cannot fill with adequate blood before the next pump, leading to fatigue, shortness of breath, and fluid buildup. By improving relaxation, urolithin A targets one of the core mechanical failures of the disease.

Furthermore, the study found that urolithin A helped reduce tissue scarring, also known as fibrosis. Fibrosis is a primary driver of heart stiffness. By mitigating this scarring, the heart tissue remained more pliable and resilient in the laboratory models.

How Urolithin A Supports Cellular Energy

While the exact mechanisms are still being explored, urolithin A is highly regarded in functional medicine circles for its role in mitochondrial health. Mitochondria are the energy powerhouses of our cells. Because the heart must beat continuously without ever taking a break, heart cells are densely packed with mitochondria to keep up with the immense energy demand.

Urolithin A has been shown in previous research to stimulate a process called mitophagy—the cellular cleanup of old, damaged, or dysfunctional mitochondria. By clearing out cellular debris and encouraging the growth of fresh, efficient mitochondria, urolithin A may provide the heart cells with the clean energy they need to contract and, just as importantly, to relax.

Looking Ahead: Diet, the Microbiome, and Heart Health

Because urolithin A production is entirely dependent on the presence of specific gut bacteria, simply eating more pomegranates or walnuts does not guarantee that your body will produce a therapeutic amount of the compound. Current microbiome research suggests that a significant portion of the population may lack the specific microbial flora required to efficiently convert ellagitannins into urolithin A.

This variability highlights the importance of overall gut health. A diet rich in diverse, high-fiber plant foods can help cultivate a robust microbiome, potentially improving your body's ability to extract and manufacture these vital postbiotics.

While these early-phase findings are exciting, it is crucial to remember that dietary interventions and emerging natural compounds should not replace conventional medical care. Anyone experiencing symptoms of heart failure or currently undergoing treatment should never stop, avoid, or delay their prescribed therapies. Clinical trials in humans are still heavily needed to confirm if dietary interventions or targeted urolithin A supplementation can effectively treat HFpEF in everyday patients.

For now, incorporating ellagitannin-rich foods like pomegranates, berries, and walnuts into a balanced, whole-foods diet remains a safe, foundational strategy for supporting long-term cardiovascular and metabolic health.